Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The SYRE news page on Stock Titan aggregates company press releases, clinical updates, and capital markets announcements so readers can follow how Spyre’s programs and corporate activities evolve over time.
In its public communications, Spyre highlights a pipeline of investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, with programs such as SPY001, SPY002, SPY072, and SPY003. News items frequently cover interim Phase 1 data, such as reports that SPY003 was well tolerated and exhibited an approximately 85-day half-life, and that SPY002 and SPY072 showed pharmacokinetic profiles supporting potential quarterly or twice-yearly maintenance dosing. Updates also describe the design and enrollment status of the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
Investors and followers of SYRE can also find announcements about stock offerings, use of proceeds, and equity inducement awards granted under the company’s equity plans, as well as participation in scientific congresses and investor conferences. Together, these news items provide insight into Spyre’s clinical development progress, financing activities, and broader corporate strategy as disclosed by the company.
For users tracking SYRE, this page offers a centralized view of Spyre Therapeutics’ official news flow, including trial milestones, interim study findings, and key financing events drawn from press releases and related disclosures.
Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 46,600 shares granted to two non-executive employees under the 2018 Plan. The grants were approved March 2, 2026 and comply with Nasdaq Listing Rule 5635(c)(4).
The options carry a 10-year term, an exercise price of $42.49 per share (closing price on March 2, 2026), and vest 25% after one year then monthly at 1/48th thereafter, subject to continuous service and plan terms.
Spyre Therapeutics (NASDAQ: SYRE) announced management will participate in three investor conferences in March 2026: TD Cowen Health Care (Boston) on March 3, Leerink Global Healthcare (Miami) on March 9, and Jefferies Biotech on the Beach (Miami) on March 10.
Management will host one-on-one investor meetings and provide live audio webcasts and replays via the company investor events website.
Spyre Therapeutics (NASDAQ:SYRE) reported Q4 and full-year 2025 results and corporate updates on Feb 19, 2026. Key highlights: $756.5 million in cash and marketable securities as of Dec 31, 2025, expected runway into H2 2028; six proof-of-concept readouts planned in 2026 across SKYLINE and SKYWAY.
The company advanced SPY001, SPY002, SPY003, and SPY072 into Phase 2 trials, raised gross proceeds of $316.2 million in Oct 2025, and appointed a new Chief Commercial Officer.
Spyre Therapeutics (NASDAQ: SYRE) announced scientific presentations at the 21st ECCO Congress (Feb 18-21, 2026) covering interim Phase 1 results for SPY003, the SKYLINE platform trial, and preclinical mouse data showing dual TL1A/IL-23 targeting outperformed monotherapies.
SPY003 was well tolerated to 20 weeks, showed a differentiated PK profile consistent with Q3M or Q6M dosing, and reduced downstream cytokines.
Spyre Therapeutics (NASDAQ: SYRE) granted inducement stock options totaling 30,200 shares to five non-executive employees under its 2018 Equity Inducement Plan.
Approved on Feb 2, 2026, the options have a 10-year term, $32.75 exercise price (Feb 2 close) and vest 25% after one year then monthly at 1/48th, subject to continuous service.
Spyre Therapeutics (NASDAQ: SYRE) announced that its Compensation Committee approved inducement stock options to purchase 108,155 shares for employee Kate Chevlen in connection with her appointment as Chief Commercial Officer.
The grant was approved on January 22, 2026, provided under the 2018 Equity Inducement Plan, and was disclosed as material to the employee's acceptance under Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and an exercise price of $34.09, equal to Spyre's Nasdaq closing price on January 22, 2026. Vesting is 1/4 on the first anniversary of the start date, then 1/48 monthly thereafter, subject to continuous service and the 2018 Plan terms.
Spyre Therapeutics (NASDAQ: SYRE) outlined a 2026 plan anchored by six expected proof-of-concept (POC) readouts: three from the SKYLINE Phase 2 platform in ulcerative colitis and three from the SKYWAY Phase 2 basket trial in RA, PsA, and axSpA. Enrollment for SKYLINE Part A exceeded expectations with SPY001 enrollment complete and Part A readouts now anticipated to begin in Q2 2026. SKYWAY readouts across all indications are expected in 4Q 2026. The company appointed Kate Tansey Chevlen as Chief Commercial Officer and reported a pro forma cash, cash equivalents, and marketable securities balance of $783M as of Sept 30, 2025, which it expects to fund operations into the second half of 2028.
Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 42,000 shares granted to six non-executive employees under the 2018 Equity Inducement Plan. The grants were approved on January 2, 2026 and were described as material to each employee's acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have a 10-year term, an exercise price of $30.58 (Spyre closing price on January 2, 2026), and vest one-fourth on the first anniversary of each employee’s start date with the remainder vesting monthly at 1/48th thereafter, subject to continuous service and the terms of the 2018 Plan.
Spyre Therapeutics (NASDAQ: SYRE) announced that its independent Compensation Committee approved inducement stock option awards to two non-executive employees under the Spyre 2018 Equity Inducement Plan.
The awards total 20,300 options, were approved on December 1, 2025, have a 10-year term, and an exercise price of $28.66 (Nasdaq closing price on December 1, 2025). Vesting is one-quarter on the first anniversary of each employee’s start date and then 1/48th monthly thereafter, subject to continuous service; the options are subject to the 2018 Plan and were described as material to each employee’s acceptance under Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics (NASDAQ: SYRE) announced that its independent Compensation Committee approved inducement stock options for 19,600 shares to one non-executive employee under the 2018 Equity Inducement Plan. The grants were approved on November 3, 2025, have a 10-year term, and an exercise price equal to the $23.78 Nasdaq closing price on November 3, 2025. Vesting is one-fourth on the first anniversary of the employee’s start date and then 1/48th monthly thereafter, subject to continuous service. The options were described as material to the employee’s acceptance of employment under Nasdaq Listing Rule 5635(c)(4).